Design Therapeutics Inc(DSGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:01 PM ET (Korea 10/29 05:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.18 | Insider Own | 44.74% | Shs Outstand | 62.6M | Perf Week | 3.26% |
| Market Cap | 0.69B | Forward P/E | - | EPS next Y | -20.72% | Insider Trans | - | Shs Float | 34.6M | Perf Month | -12.2% |
| Enterprise Value | 0.49B | PEG | - | EPS next Q | -0.34 | Inst Own | 60.88% | Short Float | 19.24% | Perf Quarter | -12.2% |
| Income | -0.07B | P/S | - | EPS this Y | -7.86% | Inst Trans | 26.83% | Short Ratio | 11.2 | Perf Half Y | -29.83% |
| Sales | 0.00B | P/B | 3.44 | EPS next 5Y | -16.98% | ROA | -32.33% | Short Interest | 6.65M | Perf YTD | 18.12% |
| Book/sh | 3.23 | P/C | 3.34 | EPS past 3/5Y | -2.32% -52.23% | ROE | -34.13% | 52W High | -35.77% ($17.25) | Perf Year | 65.87% |
| Cash/sh | 3.31 | P/FCF | - | Sales past 3/5Y | - | ROIC | -34.72% | 52W Low | 79.87% ($6.16) | Perf 3Y | 448.51% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -5.51% | Gross Margin | - | Volatility(W/M) | 4.74% 5.98% | Perf 5Y | -28.52% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.66 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 18.86 | EPS Q/Q | 3.87% | Profit Margin | - | RSI (14) | 46.47 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 18.86 | Sales Q/Q | - | SMA20 | 0.61% ($11.01) | Beta | 1.72 | Target Price | $21.71 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/3 | SMA50 | -13.77% ($12.85) | Rel Volume | 0.88 | Prev Close | $10.63 |
| Employees | 124 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 7.06% - | SMA200 | -8.84% ($12.15) | Avg Volume(3M) | 0.59M | Price | $11.08 |
| IPO | 2021/3/26 | Option/Short | Yes/Yes | Trades | 6706 | Volume | 521,224 | Change | 4.23% |
🧬 Design Therapeutics (DSGN) is a clinical-stage biotech company targeting serious hereditary degenerative diseases caused by nucleotide repeat expansion. Through its proprietary GeneTAC small-molecule platform, the company aims to address the root cause of intractable diseases with well-defined genetic origins, such as Friedreich's ataxia. It is headquartered in the United States and operates with a research-and-development focus.
Over the past 1 year, roughly in the middle
36% below its 1-year high.
Traded about as much as usual. That is 88% of its average volume.
DSGN has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -7.9% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -28.5%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 60.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #191 of 594 in the industry
Based on market cap of $693M.
ACHV#188 Achieve Life Sciences Inc $705M PER - 
IAM#189 Iambic Therapeutics Inc $701M PER - 
SLDB#190 Solid Biosciences Inc $695M PER - DSGN#191 Design Therapeutics Inc $693M PER - 
SLBT#192 SL Science Holding Ltd $679M PER - 
FAQ
What kind of company is DSGN?
DSGN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DSGN?
The market cap of DSGN is approximately $693M, ranking 2,896 within its sector.
What is the 52-week high and low for DSGN?
DSGN has recorded a 52-week high of $17.25 and a low of $6.16.
